Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Skin cancer

DREAMseq of therapy for BRAF-mutant melanoma

Nature Reviews Clinical Oncology volume 20, page 1 (2023)Cite this article

Subjects

Access through your institution
Buy or subscribe

The choice of frontline therapy for patients with advanced-stage BRAF-mutant melanoma has been unclear: responses tend to be more common with BRAF-targeted therapy but more durable with immune-checkpoint inhibitors (ICIs). Moreover, initial use of one strategy might affect responses to the other. Now, data from the phase III DREAMseq trial indicate an optimal treatment sequence.

In this trial, 265 patients with previously untreated BRAFV600-mutant metastatic melanoma were randomly assigned (1:1) to receive dual ICI therapy with nivolumab and ipilimumab (arm A) or dual BRAF and MEK inhibitor therapy with dabrafenib and trametinib (arm B). Upon disease progression patients could cross over to receive the alternative combination in arms C and D, respectively. The primary end point was 2-year overall survival (OS).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. DREAMseq of therapy for BRAF-mutant melanoma. Nat Rev Clin Oncol 20, 1 (2023). https://doi.org/10.1038/s41571-022-00708-z

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-022-00708-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing